工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Polarization of Tumor Cells and Tumor-Associated Macrophages: Molecular Mechanisms and Therapeutic Targets.
Polarization of Tumor Cells and Tumor-Associated Macrophages: Molecular Mechanisms and Therapeutic Targets.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤相关巨噬细胞(TAMs)是实体瘤的主要组成部分,其高丰度通常与不良临床结局相关。这些高度可塑的免疫细胞在免疫抑制性肿瘤微环境(TME)中发生动态功能变化,与恶性细胞进行相互交互。这种双向通讯促进了同时发生的表型转化:肿瘤细胞向侵袭性间充质状态转变,而TAMs则发展出免疫抑制性、促肿瘤特性。越来越多的证据强调,以脂质代谢失调、氨基酸利用异常和糖酵解活性改变为特征的代谢重编程,是协调这一病理共生关系的基本分子基础。
然而,目前缺乏对代谢重编程如何特异性协调肿瘤细胞与TAMs相互极化的全面理解。本综述深入探讨了调控这一共极化过程的分子机制,详细阐述了关键转录调控因子、重要信号通路以及TME中适应性表型的维持。
此外,本综述批判性评估了旨在破坏这一联盟的有前景的治疗策略,包括使用代谢靶向药物、工程化嵌合抗原受体巨噬细胞以及TAM选择性纳米颗粒递送系统。这些见解为开发下一代癌症免疫疗法提供了重要基础,该疗法聚焦于重编程病理性极化动态,以克服治疗耐药并改善临床结局。
Tumor-associated macrophages (TAMs) are prominent constituents of solid tumors, and their prevalence is often associated with poor clinical outcomes. These highly adaptable immune cells undergo dynamic functional changes within the immunosuppressive tumor microenvironment (TME), engaging in reciprocal interactions with malignant cells.
This bidirectional communication facilitates concurrent phenotypic transformation: tumor cells shift toward invasive mesenchymal states, whereas TAMs develop immunosuppressive, pro-tumorigenic traits. Increasing evidence highlights metabolic reprogramming, characterized by dysregulation of lipid metabolism, amino acid utilization, and glycolytic activity, as the fundamental molecular basis orchestrating this pathological symbiosis.
However, a comprehensive understanding of how metabolic reprogramming specifically coordinates the mutual polarization of tumor cells and TAMs is lacking. This review thoroughly examines the molecular mechanisms governing this co-polarization process, detailing critical transcriptional regulators, essential signaling pathways, and the maintenance of adaptive phenotypes within the TME.
Furthermore, this review critically assesses promising therapeutic strategies aimed at disrupting this alliance, including the use of metabolically targeted agents, engineered chimeric antigen receptor macrophages, and TAM-selective nanoparticle delivery systems. These insights provide a crucial foundation for the development of next-generation cancer immunotherapies focused on reprogramming pathological polarization dynamics to overcome treatment resistance and improve clinical outcomes.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。